연구성과로 돌아가기
2020 연구성과별 연구자 정보 (1203 / 2428)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| march5 Governs the Convergence and Extension Movement for Organization of the Telencephalon and Diencephalon in Zebrafish Embryos | Rhee, Myungchull | Rhee, M | 6 | 교신저자 | Chungnam Natl Univ, Grad Sch, Dept Life Sci, BK21 Plus Program, Daejeon 34134, South Korea | mrhee@cnu.ac.kr; | ||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Catenacci, Daniel V. T. | Catenacci, DVT | 1 | 교신저자 | Univ Chicago, Med Ctr, Chicago, IL 60637 USA | K-4177-2019 | Catenacci, Daniel | dcatenac@bsd.uchicago.edu; | ||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Kang, Yoon-Koo | Kang, YK | 2 | Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea | ABL-4264-2022 | Kang, Yoon-Koo | dcatenac@bsd.uchicago.edu; | |||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Park, Haeseong | Park, H | 3 | Washington Univ, Sch Med, St Louis, MO USA | AAL-7982-2021 | Park, Haeseong | dcatenac@bsd.uchicago.edu; | |||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Uronis, Hope E. | Uronis, HE | 4 | Duke Univ, Med Ctr, Durham, NC USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Lee, Keun-Wook | Lee, KW | 5 | Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Ng, Matthew C. H. | Ng, MCH | 6 | Duke NUS Med Sch, Natl Canc Ctr, Singapore, Singapore | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Enzinger, Peter C. | Enzinger, PC | 7 | Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Park, Se Hoon | Park, SH | 8 | Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea | GMX-1199-2022 | Park, Se Hoon | 0000-0001-5084-9326 | Park, Se Hoon | dcatenac@bsd.uchicago.edu; | |
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Gold, Philip J. | Gold, PJ | 9 | Swedish Canc Inst, Seattle, WA USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Lacy, Jill | Lacy, J | 10 | Yale Sch Med, New Haven, CT USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Hochster, Howard S. | Hochster, HS | 11 | Yale Sch Med, New Haven, CT USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Hochster, Howard S. | Hochster, HS | 11 | Rutgers Canc Inst New Jersey, New Brunswick, NJ USA | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Oh, Sang Cheul | Oh, SC | 12 | Korea Univ, Guro Hosp, Seoul, South Korea | dcatenac@bsd.uchicago.edu; | |||||
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | Kim, Yeul Hong | Kim, YH | 13 | Korea Univ, Anam Hosp, Seoul, South Korea | 0000-0002-2555-2333 | Kim, Yeul Hong | dcatenac@bsd.uchicago.edu; |
페이지 이동: